Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Duolingo Inc (DUOL) vs Pfizer Inc (PFE) Price & Performance

Duolingo IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Duolingo Inc vs Pfizer Inc — how do they compare? Duolingo Inc trades at $135.31 (market cap $6.42B), while Pfizer Inc trades at $26.61 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 24× Duolingo Inc's market cap, and Pfizer Inc pays a 6.36% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals.

DUOLPFE
Market Cap
$6.42B$154.18B
Sector
TechnologyHealth
52-Week High
$369.19$28.56
52-Week Low
$90.03$23.60
Enterprise Value
$5.19B$205.67B
Volume
29,869,932
Dividend Yield
6.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Duolingo Inc

DUOL trades at $130.9, up 6.79% in 24 hours, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates at $0.66 versus $0.604 expected, driven by 23% daily active user growth. However, a lower Q3 revenue forecast has tempered optimism. Fundamentals show robust revenue growth to $1.04B in 2025 and a net income margin of 35.87%, though valuation multiples like P/E of 15.47 and P/S of 5.6 suggest premium pricing.

Outlook is mixed: strong user engagement and profitability support upside, but monetization concerns and competitive pressures pose risks. Analysts are cautious with a $121 consensus price target below current levels, highlighting execution challenges in converting growth to sustained revenue.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Duolingo Inc

Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue

Read more on DUOL

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE